AdvaMed® Response to House Privacy Working Group RFI 

Join Genpact as they help Medtech Service leaders tackle the margin challenge by transitioning to a Predictive Triage & Guaranteed Uptime model.

AdvaMed® 2025 Membership Has Its Privileges highlights major legislative and regulatory wins delivering millions in savings and new revenue for members.

AdvaMed’s® Comment Letter to ASTP/ONC, outlines concrete policy reforms across FDA oversight, CMS payment pathways, and HIPAA data-sharing rules to accelerate patient access to AI-enabled medical technologies. As AI-enabled medical devices transform patient care, outdated regulatory, coverage, and privacy frameworks are slowing the pace of adoption.

WASHINGTON—AdvaMed, the MedTech Association®, today announced that Jacob “Jake” Leach, President and Chief Executive Officer at Dexcom, will serve as the next chair of theAdvaMed® Diabetes Sector, succeeding Chris Scoggins, Executive Vice President of Diabetes Care at Abbott. TheAdvaMed® Diabetes Sector represents the world’s leading companies producing technology across the spectrum of diabetes care. 

WASHINGTON—AdvaMed, the MedTech Association®, the world’s largest medtech trade association, representing over 650 medical technology innovators, has filed an amicus curiae brief in the Walker v. Becton, Dickinson and Company and C. R. Bard, Inc. case now before the Georgia Court of Appeals, urging the Court to reverse a trial court ruling that allowed unreliable expert testimony on ethylene oxide (EtO) exposure.

February is American Heart Month—a time to spotlight cardiovascular disease and highlight innovations that can improve patient outcomes. For the medtech community, it’s an opportunity to address persistent gaps in care through technology, data, collaboration, and policy advancement. Despite progress in treating heart conditions, sleep disorders—especially sleep apnea—remain a significant and underrecognized contributor to poor cardiovascular outcomes.1 Tackling this issue requires clinical awareness and supportive policies for timely diagnosis, coverage, and care beyond traditional settings.

AdvaMed® comment letter to the OIG’s recommends updates to safe harbors, value-based arrangements, & oversight to support value-driven healthcare.

WASHINGTON, D.C.—AdvaMed, the world’s largest trade association representing medical technology innovators, announced that its Medical Device Submissions Workshop Series (February 23-27 in Washington, D.C.) has been officially approved for RAC recertification credits by the Regulatory Affairs Professionals Society (RAPS).